Clomiphene for Men

Clomiphene citrate is a selective estrogen receptor modulator. The FDA label approves it for exactly one thing: the treatment of ovulatory dysfunction in women desiring pregnancy. Nothing on that label concerns male testosterone. Yet the 2024 AUA testosterone deficiency guideline lists clomiphene citrate in its table of alternative therapies under a footnote reading not FDA-approved for use in males. Both things are true at once, and that tension is the whole story of this drug in men.

The mechanism is indirect. Estrogen normally tells your hypothalamus and pituitary to ease off on gonadotropin release. Clomiphene occupies those receptors, the brake comes off, and gonadotropin secretion increases so your own testes produce more testosterone. LH climbs, FSH climbs, and because FSH drives sperm production, spermatogenesis keeps running rather than shutting down. A testosterone gel or injection does the reverse: it supplies the hormone from outside and the axis goes quiet. That indirect route sets a hard boundary. Clomiphene raises the signal reaching your testes. It cannot make a testis answer a signal it can no longer answer. Where the fault sits in the hypothalamus or pituitary there is something to amplify. Where the testicular tissue itself has failed, turning up LH accomplishes very little. This is why the drug belongs to the secondary hypogonadism conversation rather than the primary one.

Read the label closely and the first surprise is chemical. Clomiphene citrate is a mixture of two geometric isomers, cis (zuclomiphene) and trans (enclomiphene), containing between 30% and 50% of the cis-isomer. The same document adds that zuclomiphene has greater estrogenic activity than enclomiphene and a longer half-life, with detectable levels persisting for longer than a month. So a 50 mg tablet is not one drug. It is the compound doing the useful gonadotropin work alongside another with a distinctly estrogenic character.

Over weeks of dosing that balance drifts hard. Among 15 men taking 25 mg daily for at least six weeks, median zuclomiphene concentration was 44.0 ng/mL against 2.2 ng/mL for enclomiphene, a ratio of 20 to 1. A controlled study in healthy men found the zuclomiphene urinary detection window ran from 121 days to more than 261 days after a single 30-day course. The isomer nobody was aiming for accumulates and lingers, which is the mechanistic argument usually offered for the estrogenic complaints reported on clomiphene.

Enclomiphene isolates the trans-isomer to sidestep that accumulation. A retrospective comparison of 46 men on enclomiphene and 32 on clomiphene found both raised total testosterone, while only enclomiphene significantly raised FSH, LH and total motile sperm count. That is one small retrospective series and not a verdict. If the isolated isomer is what you are weighing, the enclomiphene page covers its supply and regulatory picture, which differs sharply from the generic tablet described here.

The largest single figure comes from a 332-man cohort with a mean age of 36.2. Mean total testosterone rose 329.2 ng/dL, with a 95% confidence interval of 307.4 to 351.0, and 73% gained at least 200 ng/dL. A separate series of 46 men tracked durability instead: total testosterone went from 228 ng/dL at baseline to 612 at one year, 562 at two years and 582 at three years, all at P<0.001. Whatever else is uncertain, the effect does not appear to fade over the first few years.

For scale, the AUA defines treatment success as total testosterone in the 450 to 600 ng/dL band, the middle tertile of most laboratory reference ranges, alongside improvement in symptoms. In healthy men rather than hypogonadal ones, a controlled 30-day course of 50 mg daily raised mean testosterone 146%, LH 177% and FSH 170% above baseline. That study existed to characterize clomiphene as a doping agent, which tells you the hormonal effect is not subtle.

Breadth of evidence is the weak spot. A systematic review pooling 19 studies and 1,642 men reported increases in total testosterone, free testosterone, LH, FSH, SHBG and estradiol, but most of those studies were small and observational. A 2024 pharmacology review states outright that clomiphene's long-term efficacy and safety remain inadequately understood.

Read the numbers above as consistent signals from modest studies. They are not settled trial evidence.

Start with the diagnosis, because clomiphene is not a treatment for feeling tired. The AUA sets a total testosterone below 300 ng/dL as the cut-off, measured on two separate occasions, both in the early morning, and adds that the clinical diagnosis is made only when low levels are combined with symptoms or signs. It also directs clinicians to measure serum luteinizing hormone in anyone with low testosterone, which is the test that separates a signaling problem from a testicular one.

The candidate profile in the literature skews young. In an 86-man series with a mean age of 29, infertility was the reason for choosing clomiphene over testosterone in 64% of cases. That is the pattern. If children are still in the plan, or you would rather not hand your own hormone production over to an outside supply in your thirties, the calculation is different from a 60-year-old with no fertility plans at all.

One intuition worth dropping is that low gonadotropins predict a good response. In the 332-man cohort, baseline LH and FSH did not predict the testosterone response to clomiphene. Gonadotropin levels still matter for working out what is wrong. They are not a screening test for who will do well on the drug, and that call sits with a clinician reading your whole workup rather than a single number.

On raw hormone numbers the two are closer than the marketing suggests. A comparison across treatment groups found median total testosterone rising from 247 to 504 ng/dL on clomiphene and from 230 to 412 ng/dL on testosterone gel, with satisfaction scores similar between groups. The AUA cites two randomized trials in which sperm concentration was maintained on SERMs but significantly decreased on exogenous testosterone. The divergence is not in the testosterone level. It is downstream of it.

That downstream difference is why the guideline is blunt. Exogenous testosterone therapy should not be prescribed to men who are currently trying to conceive, a Strong Recommendation at Grade A evidence, because it interrupts spermatogenesis and can produce severely oligospermic or azoospermic states. Return of sperm after stopping can take up to two years in some cases, and some men never see it return. A 2025 review describes the same mechanism from the other side: exogenous testosterone and anabolic steroids suppress the axis, reduce intratesticular testosterone and impair spermatogenesis.

Clomiphene is not the only fertility-preserving option either. The guideline permits aromatase inhibitors, human chorionic gonadotropin, selective estrogen receptor modulators, or a combination, in men with testosterone deficiency desiring to maintain fertility, at Conditional Recommendation and Grade C. A randomized trial in 282 men wishing to preserve fertility compared clomiphene, hCG and both together and found all three raised testosterone comparably, with the combination scoring best on the symptom questionnaire.

There is no approved male dose, so the honest answer is whatever published regimens used. The AUA table lists clomiphene citrate at 25 to 50 mg orally every one to two days, with time to maximum concentration of 5 hours and a half-life of 5 to 7 days. The largest prospective series started at 25 mg every other day and titrated toward a target of 550 plus or minus 50 ng/dL, with 70% remaining on 25 mg every other day across a mean of 19 months.

That last figure deserves a pause, because the dose quoted around the internet for this drug runs much higher. In that series most never needed to climb. Daily 50 mg dosing does appear in the literature, but the controlled 30-day study that used it was designed to characterize clomiphene as a performance-enhancing drug and map its urinary detection window. It was never designed to establish a therapeutic dose. Different question, different regimen, and no template for treatment.

One practical wrinkle: the US supply comes in a single strength. Every clomiphene citrate product in the federal acquisition-cost survey is a 50 mg tablet, so a 25 mg dose means splitting a scored tablet. That is routine, but confirm it with the prescriber and the pharmacy rather than assuming, since it changes the arithmetic on a month's supply. Your prescriber sets the dose and decides whether the drug fits at all.

The label's most serious warning is ocular. Blurring or other visual symptoms such as spots or flashes, described as scintillating scotomata, may occur, and these increase in incidence with increasing total dose or therapy duration. Most resolve after stopping, but the label states directly that the visual disturbances may be irreversible, especially with increased dosage or duration of therapy. Postmarketing reports include temporary or prolonged loss of vision.

A new visual symptom is a call-the-prescriber event, not a wait-and-see one.

Mood is the other complaint that actually changes decisions. Postmarketing surveillance lists anxiety, irritability, mood changes and psychosis among psychiatric events, while depression, insomnia and nervous tension sit among events reported in fewer than 1% of trial participants. The AUA table adds visual symptoms, flushing, headache and abdominal discomfort for the drug. A systematic review across 19 studies noted side effects prevalent in fewer than 10% of the study populations, with no serious adverse events reported.

Monitoring is not optional, because clomiphene lifts estradiol along with testosterone. The pooled review recorded increases in estradiol as well as testosterone, LH, FSH and SHBG, and the AUA directs clinicians to measure serum estradiol where breast symptoms or gynecomastia are present. The label also carries contraindications that travel across to male use: liver disease or a history of liver dysfunction, and uncontrolled thyroid or adrenal dysfunction or an organic intracranial lesion such as a pituitary tumor. Whether any of those rule you out is a clinician's judgment on your history.

A legitimate online path for this drug moves slower than a weight-loss consult, and that is the point. The diagnostic standard is two total testosterone measurements on separate occasions, both taken in the early morning, plus a serum luteinizing hormone level. A platform willing to write a clomiphene prescription off a symptom questionnaire alone has skipped the step that determines whether the drug can do anything for you.

Ask one specific question before paying: is the prescription for the FDA-approved generic tablet or for a compounded preparation? Clomiphene citrate has approved generic products on the US market. Compounded drugs are a different regulatory category and the FDA does not review them for safety, effectiveness or quality. The AUA takes the parallel position on testosterone itself, advising that commercially manufactured products be prescribed rather than compounded ones where possible.

Off-label prescribing is ordinary and lawful. A clinician may prescribe an approved drug for an unapproved use where clinical judgment supports it, and the guideline explicitly contemplates SERMs for exactly this purpose. What off-label status does change is paperwork. Coverage decisions, prior authorization and pharmacy questions all get more likely, which is worth raising at the first visit rather than discovering at the counter.

There is a public number for this one. The federal National Average Drug Acquisition Cost survey priced clomiphene citrate 50 mg tablets at $4.65243 per tablet, classified as generic, in the file published on September 2, 2026, down from $5.08462 in the file published a month before. That figure is what retail pharmacies pay to acquire the drug. It is not a shelf price, and it excludes dispensing fees, pharmacy margin and anything a telehealth program layers on top.

Run it against the regimens and the drug itself is cheap. At 25 mg every other day a scored 50 mg tablet covers two doses, so a month works out to roughly seven or eight tablets. At 50 mg every other day it is about 15. Even with pharmacy markup and a dispensing fee on top, the tablets stay a small line item next to two rounds of early-morning bloodwork and a consultation fee.

Which means comparing platforms on price is mostly a comparison of service. Ask what a quoted monthly figure includes: tablets alone, tablets plus the clinician visit, the initial lab panel, repeat draws after each dose change, or all of it. Two programs quoting similar monthly numbers can differ by a full lab panel, and that is the part that recurs every time the dose moves.

Judge a platform on its process rather than its landing page. The non-negotiable is sequencing: bloodwork first, prescription second, repeat bloodwork after any change of dose. The guideline expects an initial follow-up total testosterone measurement after an appropriate interval to confirm target levels have been reached. A program that never rechecks cannot tell you whether to continue, and on a drug whose ocular warning scales with total dose and duration that gap is not cosmetic.

Then look at what they tell you before you buy. Nothing here is medical advice, and no online questionnaire replaces a clinician deciding whether clomiphene suits your diagnosis, your labs and your plans. A provider comfortable with this drug will say the male use is off-label, name which product is being dispensed, and give you a route to a licensed clinician when something changes. Vagueness on any of the three is the signal.